Sign in or Join FriendFeed
FriendFeed is the easiest way to share online. Learn more »

Libby's H*O*P*E* › Comments

Libby's H*O*P*E*
Short bowel syndrome after cytoreductive surgery and HIPEC: nutritional considerations.... [J BUON. 2014 Apr-Jun] - PubMed - NCBI - http://www.ncbi.nlm.nih.gov/pubmed...
The impact of small bowel syndrome (SBS) on overall survival was very important, as the mean overall survival in the SBS group was 28.6 months vs 41 months in other cytoreductive surgery + HIPEC patients (p<0.001). - Libby's H*O*P*E*
Libby's H*O*P*E*
Aethlon Medical and Exosome Sciences Announce the Advancement of a Broad-Spectrum Cancer Detection and Monitoring Platform. ......- http://money.cnn.com/news...
In the oncology platform validation studies, 198 single point serum specimens (taken at the time of cancer diagnosis) were analyzed from patients with Glioblastoma, Metastatic Melanoma, Breast cancer, Ovarian cancer, Colorectal cancer and Pancreatic cancer, plus 20 age-matched, female and male non-cancer controls. In the studies, the ESI platform was consistently able to differentiate individuals afflicted with cancer as compared to non-cancer controls. - Libby's H*O*P*E*
Libby's H*O*P*E*
Deciphera Pharmaceuticals announces phase 1 study of altiratinib (DCC-2701; MET/TIE2/VEGFR/TRK kinase inhibitor) in advanced solid tumors. ...... http://clinicaltrials.gov/ct2...
In preclinical cancer models, altiratinib has shown promising activity against multiple tumors, including melanoma, ovarian, glioblastoma, colorectal, gastric and breast cancers. - Libby's H*O*P*E*
Libby's H*O*P*E*
Nanotax phase I clinical trial shows promise for treating advanced abdominal cancers, including ovarian. .. - See more at: http://www.kucancercenter.org/about-u... http://www.kucancercenter.org/about-u...
During the trial, five out of 21 late-stage cancer patients survived more than 400 days after being treated with Nanotax at high concentrations for more than four weeks. - Libby's H*O*P*E*
Libby's H*O*P*E*
Pre-diagnostic serum levels of inflammation markers and risk of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial..... [Gynecol Oncol. 2014] - PubMed - NCBI - http://www.ncbi.nlm.nih.gov/pubmed...
These results suggest that CRP, IL-1α, IL-8, and TNF-α are associated with increased risk of subsequently developing ovarian cancer. - Libby's H*O*P*E*
Libby's H*O*P*E*
3V Biosciences opens 1st in human phase 1 study of TVB-2640 (FASN inhibitor) in patients with advanced stage malignant solid tumors - Full Text View - ClinicalTrials.gov - http://clinicaltrials.gov/ct2...
A 2012 preclinical study reported that fatty acid synthase (FASN) expression associated with NAC1 is a potential therapeutic target in ovarian clear cell carcinomas. Review at http://www.ncbi.nlm.nih.gov/pubmed... - Libby's H*O*P*E*
Libby's H*O*P*E*
Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer - ClinicalTrials.gov - http://clinicaltrials.gov/ct2...
MGCD516 is a receptor tyrosine kinase (RTK) inhibitor shown in preclinical models to inhibit a closely related spectrum of RTKs including MET, AXL, MER, and members of the VEGFR, PDGFR, DDR2, TRK and Eph families. - Libby's H*O*P*E*
Libby's H*O*P*E*
2014 ASCO: Almac Validates Novel Test for Ovarian Cancer Patients...... | Business Wire - http://www.businesswire.com/news...
AADx gene expression biomarker identifies a molecular subgroup of ovarian cancer patients that has better survival following standard chemotherapy but may be disadvantaged by bevacizumab. - Libby's H*O*P*E*
Libby's H*O*P*E*
2014 ASCO: Phase 1 testing of VS-6063 (defactinib; targeting cancer stem cells) + paclitaxel (Taxol) shows early signs of clinical activity (64% clinical benefit rate) in ovarian cancer patients......- http://phx.corporate-ir.net/phoenix...
“These data continue to show that the combination of cancer stem cell-targeting agent VS-6063 and paclitaxel is well tolerated, with no unexpected toxicity or worsening of the well understood side effects of paclitaxel, and support the further study of this combination in the clinic,” said Dr. Joanna Horobin, Verastem Chief Medical Officer. “In addition to the demonstration of safety, we continue to see interesting signs of early clinical activity where 14 of 22 (64%) patients enrolled in this study achieved a best overall response of at least stable disease including two partial responses and two complete responses to date.” - Libby's H*O*P*E*
Libby's H*O*P*E*
Identifying Lynch syndrome in patients with ovarian carcinoma: the significance of tumor subtype... ... [Adv Anat Pathol. 2013] - PubMed - NCBI - http://www.ncbi.nlm.nih.gov/pubmed...
In spite of contradictory results, likely reflective of differences in study design, sample size and methodology, a recurring observation is the overrepresentation of "endometriosis-associated tumors," namely, endometrioid and clear cell subtypes, in the group of ovarian tumors with MMR deficiency. - Libby's H*O*P*E*
Libby's H*O*P*E*
Scientists from USC and NYU design a molecule that blocks cancer growth in mice - http://www.eurekalert.org/pub_rel...
Protein–protein interactions are attractive targets for drug design due to their fundamental role in biological function. However, small molecules that selectively target the intended interactions have been difficult to access using traditional drug discovery approaches. We show that compounds that reproduce key functionality at the interface between transcription factor hypoxia-inducible factor 1α (HIF1α) and coactivator p300 (or CREB binding protein, CBP) can inhibit expression of a multitude of genes under hypoxic environments. The designed inhibitors target the chosen protein–protein interaction in a predictable manner and reduce tumor growth in mouse xenograft models. - Libby's H*O*P*E*
Libby's H*O*P*E*
Molecular Genetics of Clear-Cell Renal Cell Carcinoma - http://jco.ascopubs.org/content...
At least one study has found a genomic similiarity (albeit not identifical) between renal (kidney) clear cell cancer and ovarian clear cell cancer. This finding suggests that targeted therapies used to treat RCCC could also be used to treat OCCC. - Libby's H*O*P*E*
Libby's H*O*P*E*
Circulating proteolytic signatures of chemotherapy-induced cell death in humans discovered by N-terminal labeling - http://www.pnas.org/content...
Many chemotherapeutics function by inducing cellular apoptosis, or programmed cell death, in tumor cells. Here, using a unique enzymatically driven technology, we find that numerous protein fragments are released into the bloodstream from apoptotic cells within hours after chemotherapy. These circulating signatures of cell death, if confidently assigned to tumor cells, may form the foundation for entirely novel, rapid, and inexpensive biomarkers of chemotherapeutic efficacy. Diagnostic tests to rapidly assess cell death after treatment could serve an important role in management for many cancers. - Libby's H*O*P*E*
Libby's H*O*P*E*
Adoptive T-Cell Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial (Bile Duct) Cancer - http://www.sciencemag.org/content...
Malignant tumors harbor genetic alterations. Recently, adoptive T cell therapies have taken advantage of this: T cells specific for mutations in tumors are infused into patients to generate an antitumor immune response. Although therapeutic benefit has been seen for melanomas, effectiveness against more common epithelial tumors is unclear. Using whole-exome sequencing, Tran et al. (p. 641) identified tumor-infiltrating CD4+ T cells specific for a mutated antigen expressed by a tumor from a patient with metastatic cholangiocarcinoma. Infusion of this patient with an expanded-population, mutation-specific T cell resulted in tumor regression and stabilization of disease. - Libby's H*O*P*E*
Libby's H*O*P*E*
2014 AACR: Immunovaccine to Present Data on Cancer Vaccine Combination Therapies at the 2014 AACR Annual Meeting - MarketWatch - http://www.marketwatch.com/story...
Combining with cyclophosphamide and the checkpoint inhibitor anti-PD-1 enhances the therapeutic potential of vaccine. - Libby's H*O*P*E*
Libby's H*O*P*E*
Redistribution of resistance and sensitivity to platinum during the observation period following treatment of epithelial ovarian cancer. [Mol Clin Oncol. 2014] - PubMed - NCBI - http://www.ncbi.nlm.nih.gov/pubmed...
Therefore, we considered it justified to classify patients with clear cell/mucinous adenocarcinoma who relapsed within 12 months as platinum-resistant and those who relapsed after 12 months as platinum-sensitive. - Libby's H*O*P*E*
Libby's H*O*P*E*
Dasatinib (BMS-35482) Interacts Synergistically With Docetaxel, Gemcitabine, Topotecan, and Doxorubicin in Ovarian Cancer Cells With High SRC Pathway Activation and Protein Expression... [Int J Gynecol Cancer. 2014] - PubMed - NCBI - http://www.ncbi.nlm.nih.gov/pubmed...
Dasatinib in combination with relapse chemotherapeutic agents seems to interact in a synergistic or additive manner in cells with high SRC pathway activation and protein expression. - Libby's H*O*P*E*
Libby's H*O*P*E*
Epigenetic determinants of ovarian clear cell carcinoma biology.... [Int J Cancer. 2013] - PubMed - NCBI - http://www.ncbi.nlm.nih.gov/pubmed...
Preclinical study results suggest that decitabine may be effective against ovarian clear cell cancer. - Libby's H*O*P*E*
Libby's H*O*P*E*
Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies.... [Invest New Drugs. 2013] - PubMed - NCBI - http://www.ncbi.nlm.nih.gov/pubmed...
Eight patients achieved stable disease (SD) ≥ 6 months (six platinum failures) and one patient with platinum-resistant ovarian cancer, partial response (PR) (total SD ≥ 6 months/PR = 9, 16.4 %). - Libby's H*O*P*E*
Libby's H*O*P*E*
2013 AACR-NCI-EORTC Mtg: Verastem's Results Support Continued Development of VS-6063 (defactinib)(FAK inhibitor) Across Multiple Tumor Types, including Ovarian .....http://www.businesswire.com/news...
Results from the Phase 1 dose escalation portion of the study were presented. Six patients with advanced or refractory ovarian cancer, all of whom had prior taxane exposure and were platinum resistant, were enrolled. Two patients demonstrated significant decreases, or normalization, of CA-125, a marker that becomes elevated with disease progression in ovarian cancer. One patient in the VS-6063 200mg BID cohort experienced an ongoing complete response as confirmed by Response Evaluation Criteria in Solid Tumors (RECIST) with repeated radiologic scans and a second patient in the VS-6063 400mg BID cohort continues to experience prolonged stabilization of her disease. Patient recruitment remains ongoing in the expansion Phase 1b open-label, multicenter portion of the study, where Verastem expects to enroll a total of approximately 15 patients at three U.S. locations. - Libby's H*O*P*E*
Libby's H*O*P*E*
Data From Phase I Clinical Trial Of Mitochondrial Inhibitor Drug ME-344 Reveals 35% Disease Control Rate in Refractory Solid Tumors - http://investor.meipharma.com/2013-10...
As reported in the abstract of the presentation, eight of the 23 patients evaluable for efficacy (35%) achieved disease control, including one confirmed partial response (PR) in a patient with refractory small cell lung cancer (duration 52+ weeks) and seven patients with prolonged stable disease (SD) ranging from 8 to 40+ weeks. The maximum tolerated dose was established at 10 mg kg delivered on a weekly schedule. Dose limiting toxicity of Grade 3 neuropathy was observed at 15 mg/kg and 20 mg/kg. Based on these findings, MEI Pharma is actively preparing for a phase Ib clinical trial of ME-344 in combination with Hycamtin (topotecan) in small cell lung cancer and ovarian cancer, which it expects to initiate during the second quarter of 2014.” - Libby's H*O*P*E*
Libby's H*O*P*E*
Current standards of care for chemotherapy of optimally cytoreduced advanced epithelial ovarian cancer - http://www.sciencedirect.com/science...
Platinum-taxane chemotherapy remains the standard of care for the primary treatment of optimally cytoreduced advanced epithelial ovarian cancer. Primary intraperitoneal cisplatin-based chemotherapy has been shown to improve survival in the setting of optimal residual advanced ovarian cancer. The role of bevacizumab in the primary anti-neoplastic drug management of optimal residual advanced ovarian cancer remains to be defined. - Libby's H*O*P*E*
Libby's H*O*P*E*
Phase I trial of a formulated IL-12 plasmid in combination with carboplatin and docetaxel chemotherapy in the treatment of platinum-sensitive recurrent ovarian cancer - http://www.sciencedirect.com/science...
Feasibility of a novel treatment approach involving local IL-12 gene therapy and IV standard chemotherapy for ovarian cancer is described. he combination treatment was safe and associated with anticancer efficacy and IL-12 biological activity. Addition of local IL-12 gene therapy to standard chemotherapy offers a novel approach to the treatment of advanced cancers - Libby's H*O*P*E*
Libby's H*O*P*E*
Clinical outcome and prognostic markers for patients with gynecologic malignancies in phase 1 clinical trials: A single institution experience from 1999 to 2010 - http://www.sciencedirect.com/science...
58% of patients with gynecologic cancer achieved clinical benefit, and 9.2% experienced DLT in phase 1 trials. - Libby's H*O*P*E*
Libby's H*O*P*E*
Surgical outcomes and national comprehensive cancer network compliance in advanced ovarian cancer surgery in a low volume military treatment facility - http://www.sciencedirect.com/science...
NCCN compliant treatment and survival are reportedly improved at high volume hospitals, arguing for centralization of care. The low volume hospital achieved 85% NCCN treatment compliance, 73% optimal surgical cytoreduction, and 37 month overall survival rates. Hospital volume alone is not a reliable metric for quality patient care. - Libby's H*O*P*E*
Libby's H*O*P*E*
Overexpression of c-Abl predicts unfavorable outcome in epithelial ovarian cancer - http://www.sciencedirect.com/science...
Study on the association between c-Abl overexpression and metastasis of EOC is rare. Up-regulated c-Abl expression is associated with an unfavorable prognosis and is an independent prognostic factor for EOC. c-Abl may be a potential effective prognostic marker for EOC. - Libby's H*O*P*E*
Libby's H*O*P*E*
Pre-operative imaging with CA125 is a poor predictor for granulosa cell tumors - http://www.sciencedirect.com/science...
Granulosa cell tumors are almost exclusively complex and are most frequently greater than 10 cm. There was a near equal distribution of granulosa cell tumors with a CA125 greater than or less than 35. If complexity and a CA125 level > 35 are used to predict GCTs, we will frequently fail to predict them. - Libby's H*O*P*E*
Libby's H*O*P*E*
Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer - http://www.sciencedirect.com/science...
With HE4 and CA125 we can diagnose the aggressive type II EOC at all stages and ages most correctly. The diagnostic safety for the dual markers HE4 and CA125 is not acceptable in early stage type I EOC. Our results support that EOC should be looked upon as several different diseases. - Libby's H*O*P*E*
Libby's H*O*P*E*
Carcinosarcoma of the ovary: Natural history, patterns of treatment, and outcome - http://www.sciencedirect.com/science...
Ovarian carcinosarcomas are aggressive tumors with a natural history that is distinct from serous cancers. The survival for both early and late stage carcinosarcoma is inferior to serous tumors. - Libby's H*O*P*E*
Libby's H*O*P*E*
Ovarian cancer patients with localized relapse: Clinical outcome and prognostic factors - http://www.sciencedirect.com/science...
The anatomic site of relapse is a strong predictor of post-relapse survival in patients with localized recurrent ovarian cancer. Secondary cytoreductive surgery ensures a relevant survival benefit in women with localized recurrent ovarian cancer. - Libby's H*O*P*E*
Other ways to read this feed:Feed readerFacebook